Chemical Structure (Nexletol 01)
Nexletol Tablet, Film Coated
Product Images NDC 72426-118
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Nexletol (NDC 72426-118). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Esperion Therapeutics, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Nexletol 02)
This text appears to be a report of a clinical trial comparing the effectiveness of Nexletol 180mg with Placebo in reducing LDL Cholesterol levels over a period of 36 weeks. The report displays the mean percent change in LDL Cholesterol levels at baseline and week 36 for the two groups of participants: one group received Nexletol 180mg while the other received a placebo. There were 10 subjects in the Nexletol group and 99 subjects in the Placebo group.*
Principal Display Panel (30 Tablet Bottle Label)
This is information about the storage, dosage, and administration of a medication called NEXLETOL (bempedoic acid) fablefs. The package contains 30 tablets, each containing 180 mg of bempedoic acid. It is manufactured by Esperion Therapeutics, Inc. and should be stored at a temperature of 20°C to 25°C (68°F to 77°F), with excursions permitted to 15°C to 30°C (59°F to 86°F). The medication should be kept in the original package, and the desiccant should not be discarded. For more information on dosage and administration, consult the accompanying Package Insert.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
